TOKYO, Apr 27 (Pulse News Wire) – Adr120s,inc. (3750.T) resolved today to propose a name change to its upcoming 22nd annual shareholders' meeting scheduled for June 2026.
The company plans to restructure its operations to focus on cell therapy expansion, domestic manufacturing, and medical device growth. Under the new structure, ADR120S will operate as a holding company overseeing three subsidiaries: ADR Biomedical Services focusing on human cell therapies; ADR Animal Therapy expanding animal healthcare services; and ADR Genesis developing medical devices.
The changes aim to clarify roles and enhance profitability. The name change and restructuring are set to take effect on July 1, 2026, pending approval at the shareholders' meeting.
The company expects to achieve sustainable growth through clear separation of treatment and manufacturing divisions, building a high-revenue portfolio, and accelerating domestic production.
🟢 Confidence: High AI-translated content.